September 20, 2018

FunPep Co., Ltd.

Announcing Acceptance into AMED Grant Program

－ Development Project for Antibody-inducing Peptides for Familial Adenomatous Polyposis －

FunPep Co., Ltd. (“FunPep”) announces that the following research and development proposal, jointly submitted with Kagawa University, Osaka University and Kyoto Prefectural University of Medicine, has been selected by the Japan Agency for Medical Research and Development ("AMED") for the FY2018 Medical Research and Development Programs Focused on Technology Transfers: Acceleration Transformative Research for Medical Innovation Set-up Scheme (ACT-MS).

R&D Project Name	Development of Vaccine Therapy for Familial Adenomatosis Polyposis
Representative Institution	Kagawa University
Project Leader	Akira Nishiyama (Dept. of Pharmacology, Kagawa Univ.)
Set-up Company	FunPep, Co., Ltd.

Familial adenomatous polyposis is an inherited disorder that causes the development of numerous (more than 100) adenomas (polyps) in the colon, and if left untreated, almost all patients will develop colon cancer and die. Surgical colorectal resection is used to prevent the development of colorectal cancer, but it causes problems such decreased quality of life due to sequelae (after-effects) such as intestinal obstruction, diarrhea, soft stool, and dehydration. In addition, although clinical trials of drug therapies and endoscopic polypectomy as new treatment methods have been conducted, they have not been established as actual clinical treatments at this time. There remains a need for new treatment methods that are highly effective and simultaneously less physically burdensome.

FunPep, which is in charge of future commercialization, will collaborate with Kagawa University (Representative: Prof. Akira Nishiyama, Dept. of Pharmacology, Faculty of Medicine), Osaka University (Representative: Prof. Hironori Nakagami, Dept. of Health Development & Medicine, Graduate School of Medicine), and Kyoto Prefectural University of Medicine (Prof. Hideki Ishikawa, Dept. of Molecular Targeting Prevention), as part of an industry-academia collaboration, to conduct research on antibody-inducing peptides

(therapeutic vaccines) for familial adenomatosis polyposis, including drug efficacy and compound optimization tests using animals, as well as to prepare for preclinical and clinical studies. We aim to develop a new therapeutic method using antibody-inducing peptides.

This support system supports research and development through industry-academia collaboration in order to smoothly and effectively transfer "technology seeds" from academia to industry.